Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults

• Status: Completed
• Trial end date: 2017-12-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMS
• Treatments: Orlistat

Criteria

Inclusion Criteria:

• Signed Informed Consent;

• Adults Male and Female ≥ 18 years old;

• Obesity (BMI ≥ 30kg/m2 or ≥ 27 Kg/m2 with associate risk);

Exclusion Criteria:

• Pregnancy and Lactation or women without effective contraception;

• Relevant clinical diseases;

• Obesity associated to genetic syndrome;

• Decompensated Diabetes;

• Psychiatric disorders;

• Alimentary disorders;

• Use of: anorectics, herbal weight loss and/or constipation and laxatives, in the past 30 days;

• Patients using cyclosporine or amiodarone;

• Patients with bowel disease;

• Prior bariatric surgery;

• Anemia;

• Hemoglobinopathies and coagulopathy;

• History of cancer in the past five years;

• Use of corticosteroids, oral or injectable, in the last 30 days.